Photo via South China Morning Post

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner

Read the original at South China Morning Post ↗
Cite

Cheung, E. (2026, November 2). Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner. South China Morning Post. https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3372885/drug-maker-rohto-plans-clinical-trials-hong-kong-oases-first-japan-partner

Dated from the outlet's own feed. Check the original for its byline.

South China Morning Post · collected 2026-11-02 · by Elizabeth Cheung

Quick Summary

Rohto Pharmaceutical, a Japanese drug maker, is set to conduct clinical trials in Hong Kong as part of its partnership with OASES, a Hong Kong government initiative aimed at attracting foreign investment. Kunio Yamada, Rohto's chairman and representative director, cited Hong Kong’s strong research capabilities and strategic location near mainland China as key factors in choosing the city for these trials.
Written by AI on 2026-11-02, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Rohto Pharmaceutical, a Japanese drug maker, plans to conduct clinical trials in Hong Kong, marking it as the first company from Japan to partner with the city under OASES, an investment initiative by Hong Kong's government. The decision was influenced by Hong Kong’s strong university research capabilities and its proximity to the large market of mainland China. Kunio Yamada, chairman and representative director of Rohto, highlighted these factors as key draws for expanding operations in Hong Kong.

Written for “Rohto Plans Clinical Trials in Hong Kong” on 2026-11-02, grounded in this article and the 0 other(s) covering the same event.
Why this leaning score
This article does not take a side on a contested political question, so it has no leaning score. That is an answer rather than a gap: a match report or a rescue can be warmly or critically written without being left or right, and scoring it anyway is how approval of a subject gets recorded as a political position.
No political leaning scored for article 122143 · logged 2026-11-02

Story

📰 Rohto Plans Clinical Trials in Hong Kong
Health · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
2
sentences that state something as happening or true
Uncertain
0%
0 of 2 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
63/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-02 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3547 article(s) · 7 correction(s) detected
Running correction rate · 7 correction(s)

Who wrote this

Elizabeth Cheung
13 article(s) here · 0 carrying a prediction
🔮 What Hongkongers need to know about the latest changes to the MPF scheme ‘Full portability’ will allow eligible users to transfer both employer and employee contributions to their preferred MPF scheme The South China Morning Post looks at the details of the latest changes and how they will affect employees.
🔮 Health warning over beauty jabs using dead people’s skin following Hong Kong raids Treatment attracting attention online, but health official warns product lacks clinical safety data and could pose public health risks
🔮 Raymond Tong Kai-yu spent a decade overcoming challenges in cost and production to develop a device that could change lives: a robotic hand that helps stroke patients regain mobility and relearn everyday movements.
🔮 Hong Kong private healthcare providers face new rules to make fees more transparent New rules could apply from August next year, requiring bilingual price lists, budget estimates and explanations for bills at least 20 per cent higher Private healthcare providers in Hong Kong will have to make their charges more transparent under government measures to be introduced from August next year at the earliest, including requirements to publish bilingual fee schedules and annual billing statistics.
🔮 Kai Tak Hospital opens this week: what you need to know before visiting Hong Kong’s largest public hospital begins phased operation on Monday, starting with family medicine and specialist outpatient services Hong Kong’s largest public hospital, built on the former airport site in Kai Tak, will begin its first phase of operation on Monday after more than a decade of planning and preparation.
🔮 Foreign carers for elderly to get 10 to 20% more pay than current helpers Carers must also have received elderly care training recognised by Hong Kong and possess at least three years of experience looking after older people Foreign domestic carers brought to Hong Kong to look after elderly residents under a proposed government pilot scheme would receive 10 to 20 per cent more pay than existing helpers, the labour minister has said.
🔮 Hong Kong aims to raise innovation spending to 3% of GDP by about 2030 Chief Executive John Lee unveils ambitious goal, together with measures to boost frontier technologies, including aerospace research Hong Kong will strive to raise its expenditure on innovation activities to a level equivalent to 3 per cent of gross domestic product (GDP) by around 2030, nearly double the current rate, according to the city’s first five-year plan. Chief Executive John Lee Ka-chiu unveiled the ambitious goal, together with measures to boost frontier technologies, including aerospace research, on Wednesday. Among the 22 indicators laid out in the plan, the government aims to raise the ratio of total domestic expenditure on innovation activities to GDP from 1.63 per cent in 2024 to 3 per cent around 2030.
🔮 New visa category among spate of new talent-trawling measures unveiled in city leader John Lee’s latest policy address A new visa intended to attract international talent to participate in short-term training programmes in Hong Kong could become available as early as the first quarter of next year, the South China Morning Post has learned.
Also by Elizabeth Cheung
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 13 articles by Elizabeth Cheung →

Topics

China Hong Kong Japan OASES Rohto

Subjects

China GPE · 2× Hong Kong GPE · 2× Kunio Yamada PERSON · 2× Rohto ORG · 2× Firm ORG · 1× Japan GPE · 1× Japanese NORP · 1× OASES ORG · 1× Rohto Pharmaceutical ORG · 1× the South China Morning Post ORG · 1×

Narrative

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner Firm’s chairman Kunio Yamada says city’s university research strength and proximity to mainland China are key draws Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative.
framing: assertive · carried by 1 article(s) · first seen 2026-11-02
2026-11-02 · South China Morning Post
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner · assertive framing

Claims (2 extracted, 0 hedged)

Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner Firm’s chairman Kunio Yamada says city’s university research strength and proximity to mainland China are key draws Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. asserted
it → plan → initiative
Kunio Yamada, chairman and representative director of Rohto, told the South China Morning Post in an exclusive interview that Hong Kong’s top research capabilities and proximity to the mainland attracted the firm to expand in the city. asserted
capabilities → tell → city
💬Give feedback
🕘History 🎫Support